Hair loss is a common concern, affecting approximately 80 million people in the United States. It can significantly impact quality of life, leading to reduced work productivity, anxiety, and depression. With various treatment options available, understanding their potential side effects is crucial for managing patient expectations and ensuring treatment adherence. Low-dose oral minoxidil (LDOM) has emerged as a popular and effective treatment for various types of hair loss, including androgenetic alopecia, telogen effluvium, alopecia areata, and traction alopecia. It offers an easier and more convenient alternative to topical minoxidil for many patients. However, like any medication, LDOM can have side effects, one of the most notable being a temporary increase in hair shedding, often referred to as "dread shed."
This article aims to provide a comprehensive overview of the dread shed phenomenon associated with oral minoxidil, including its causes, duration, and potential management strategies. We will delve into the findings of a recent study that investigated the impact of overlapping topical and oral minoxidil therapies on the occurrence of dread shed.
Prior to the introduction of topical minoxidil, treatment options for hair loss were limited, primarily focusing on cosmetic management. The FDA approved topical minoxidil for androgenetic alopecia (AGA) in males in 1988 and in females in 1992, marking a significant advancement in hair loss therapy. Topical minoxidil remains a widely used and effective treatment, but it requires twice-daily application, which can be cumbersome and cosmetically inconvenient for some individuals.
LDOM has gained popularity due to its ease of use and comparable efficacy. While higher doses of oral minoxidil were initially used to treat hypertension, studies have shown that LDOM has a favorable safety profile with a low risk of side effects when used for hair loss. LDOM has demonstrated effectiveness in treating hair loss in both men and women.
One notable side effect of LDOM is a temporary increase in hair shedding after treatment initiation, commonly known as "dread shed." This paradoxical shedding typically begins 2 to 4 weeks after starting treatment and can last for 3 to 6 weeks.
Read also: Treating a Dry Scalp
The proposed mechanism behind dread shed involves minoxidil-induced shortening of the telogen phase of the hair cycle. This accelerated shedding of hairs that would have naturally fallen out in the coming weeks or months. While dread shed can be distressing for patients, it is usually self-limiting, and the subsequent increase in hair density and diameter typically leads to satisfactory results.
To address the concern of dread shed, one proposed strategy is to overlap the use of maintenance topical minoxidil with oral minoxidil when initiating LDOM therapy, especially for patients already using topical minoxidil. The rationale is that since topical minoxidil can also cause initial shedding, maintaining its use might mitigate a second shedding phase when starting oral therapy.
A retrospective analysis was conducted on patients with alopecia who were prescribed LDOM at the New York University Skin and Cancer Clinic or Faculty Group Practices between January 1, 2008, and August 28, 2023. Patients were categorized based on whether they were using topical minoxidil before starting LDOM and instructed to continue its use during oral therapy initiation.
The study collected data on patient demographics, treatment protocols, and patient- and physician-reported outcomes. Statistical analysis was performed using Fisher’s exact test, with a significance level of P < .05.
Out of 280 charts reviewed, 115 patients met the inclusion criteria. Of these, 55% were females with a mean age of 47.25 years. The prescribed LDOM doses ranged from 0.625 mg to 2.5 mg daily, with a median dose of 1.25 mg/day.
Read also: Comprehensive Guide to Keratin Treatments
Thirty-seven patients (32%) were using topical minoxidil before starting LDOM and were advised to continue topical maintenance therapy for at least one month. This group consisted of 73% females with a mean age of 50.91 years and a median daily LDOM dose of 1.25 mg.
The remaining 78 patients (68%) were not using topical minoxidil before starting oral treatment. This group was predominantly male (54%) with a mean age of 45.51 years and a median daily LDOM dose of 1.25 mg.
The study found no significant difference in age or length of time between follow-up visits when comparing those who used topical minoxidil to those who did not (P = .16, P = .75).
Overall, 29.6% of patients taking LDOM reported shedding at their initial visit, and 19.1% reported shedding at their first follow-up. There was no statistically significant change in shedding reports from the initial visit to the follow-up visit (P = .09).
Six patients experienced a new onset of shedding after starting LDOM, indicating they experienced dread shed. Among the 37 patients who overlapped topical and oral therapy, 40.5% reported shedding at their initial visit, and 21.6% reported shedding at follow-up. Two patients in this group experienced dread shed.
Read also: Effective Strategies for Eyelash Regrowth
For the 78 patients who did not overlap topical therapy when starting LDOM, 24.4% reported shedding at their initial visit, and 17.9% reported shedding at follow-up. Four of these patients experienced dread shed.
The study found no statistically significant difference in the change in reported shedding between those who overlapped therapies and those who did not (P = .09). Specifically, there was no significant association between experiencing dread shed and the use of overlapping topical and oral therapy (P = .0). Similarly, no significant association was found between dread shed rates and the LDOM dose prescribed (P = .49).
The study's findings suggest that maintaining topical minoxidil when initiating LDOM does not significantly reduce the occurrence of new-onset dread shed. This indicates that continuing topical minoxidil may not be clinically beneficial when starting LDOM.
The daily or twice-daily application of topical minoxidil can be burdensome for patients, and the solutions or foams can interfere with hair care routines. Given the study's results, maintaining topical therapy during LDOM initiation may not be necessary.
The study's limitations include its retrospective design, small sample size (particularly for patients reporting dread shed), and reliance on medical records, which may contain incomplete or missing data. The study also relied on patients' self-reported levels of hair shedding, which is a subjective assessment method. Additionally, hair shedding is a multifactorial symptom, making it difficult to definitively determine the impact of overlapping medications outside of confounding factors. The study excluded patients with diagnoses other than AGA to limit factors that may contribute to hair shedding.
Despite its limitations, this study provides valuable insights into the interplay between topical and oral minoxidil. Overlapping maintenance topical minoxidil during oral minoxidil initiation does not appear to significantly impact the occurrence of new-onset hair shedding.
Importantly, only 5.2% of the patient cohort experienced dread shed, which is lower than reported in previous studies. Nevertheless, dread shed remains a significant side effect that warrants further research to better understand and address it.
While the study suggests that overlapping topical minoxidil may not prevent dread shed, other strategies can help manage this side effect:
Oral minoxidil offers a compelling alternative to topical minoxidil for treating various hair loss conditions. It provides ease of use, systemic delivery, and potentially greater efficacy for some patients. However, it is essential to be aware of the potential side effects, including dread shed, hypertrichosis, and, in rare cases, cardiovascular effects.
Dr. Michele Green, a board-certified dermatologist in New York City, highlights the benefits of oral minoxidil for patients seeking a convenient and effective hair loss treatment. She notes that oral minoxidil can be used in conjunction with other treatments, such as finasteride or spironolactone, and is often less expensive than topical formulations.
Dr. Green emphasizes the importance of consulting with a dermatologist to determine if oral minoxidil is the right treatment option and to rule out any contraindications.
Other experts in the field have also acknowledged the efficacy and safety of LDOM for hair loss. However, they stress the need for further research to optimize dosing, identify potential predictors of treatment response, and develop strategies to minimize side effects.
tags: #oral #minoxidil #hair #shedding #initial
